Spectrum Of Activity
Usual doseUTIMild or moderate SSTISevere SSTILife-threatening infectionSurgical prophylaxis1-2 g IV q12h0.5-1 g IV q12h1 g IV q12h2 g IV q12h3 g IV q12h1-2 g IV within 30-60 min prior to surgery
Safety and efficacy in pediatric patients have not been established
No dose adjustment
CrCl >30CrCl 10-30CrCl <10HDCRRTNo dose adjustmentRecommended dose IV q24hRecommended dose IV q48h1-2 g q48h (+ extra 1 g AD)
Non-HD days A quarter (1/4) of the usual dose
HD days Half of the usual dose750 mg q12h
Infection of bone
Infection of skin and/or subcutaneous tissue
Infectious disease of abdomen
Infectious disorder of joint
Lower respiratory tract infection
Pelvic inflammatory disease
Urinary tract infectious disease
Monitor renal function, electrolytes, CBC including platelets.
Toxic epidermal necrolysis
Clostridium difficile colitis
Warfarin - increased risk of bleeding
Cholera vaccine, live
Typhoid vaccine, live
Antimicrobial class: 2nd Generation Cephalosporin
Pregnancy category: B
Average serum half life: 3-4.6 hours
Urine penetration: Therapeutic
Lung penetration: Therapeutic
Biliary penetration: Therapeutic
CSF penetration: Therapeutic
Use with caution in patients with hypersensitivity to penicillins as cross-sensitivity may occur, and history of gastrointestinal disease.
Decrease in prothrombin activity and associated bleeding may occur, with increased risk in elderly and patients with renal or hepatobiliary impairment, poor nutritional status, and cancer.
Discontinue if Clostridium difficile associated diarrhea is suspected.
Monitoring recommended for overgrowth of nonsusceptible organisms and superinfection and hemolytic anemia.
Micromedex web. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 October 15]. Available from: Micromedex